Hydrogen Capsules Help Liver Disease Patient Recover Faster
Molecular Hydrogen Capsule Therapy for Primary Biliary Cholangitis With Elevated IgG4: A Case Report on Immune Marker Normalization
- Evidence type
- Case report or series · Human study
- Authors
- Yun-Ting Lin, Jeng-Wei Lu, Jung-Chun Lin, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Hsiao-Chen Liu, Kuang-Yih Wang, Feng-Cheng Liu
- Journal
- In Vivo
- Year
- 2025
- PMID
- 40295001
- Study Type
- Human
- Participants
- 1
- Delivery
- Gas (Sustained Release)
- Dose
- One H2 capsule daily for four months
- Duration
- 4 months
- Funding
- National Science and Technology Council, Taiwan (NSTC 112-2314-B-016-033); National Science and Technology Council, Taiwan (NSTC 113-2314-B-016-052); Tri-Service General Hospital, Taiwan (TSGH-E-112218); Tri-Service General Hospital, Taiwan (TSGH-E-113238)
- Conflicts of interest
- None declared
- Outcome
- Positive
- Peer Reviewed
- Yes
- Cited by
- 1 (OpenAlex, as of November 2026)
- Country
- Taiwan
TL;DR
Molecular hydrogen capsules improved liver health and immune function in a patient with a chronic autoimmune liver disease not fully helped by standard treatment.
Key Finding
In one patient with PBC inadequately controlled by standard therapy, adding molecular hydrogen capsules for four months reduced liver enzymes (AST from 279 to 95 U/l, ALT from 183 to 70 U/l) and normalized immune markers previously abnormal during disease flares.
Summary
This case report describes one 44-year-old man with primary biliary cholangitis (PBC), a chronic disease where the immune system damages bile ducts in the liver, who was not responding well to standard treatment. When molecular hydrogen capsules were added to his existing medication over four months, his liver enzyme levels improved significantly, immune markers normalized, and he reported feeling less tired and itchy. However, this is a single patient's experience, not a controlled study.
Practical Takeaway
While this case suggests molecular hydrogen capsules may have potential as an add-on treatment for PBC, this is only one patient's experience and cannot establish whether the improvement was due to the hydrogen, time, or other factors. Much larger controlled studies are needed before any conclusions can be drawn about effectiveness. Anyone with PBC considering this should discuss it with their doctor.
Abstract (excerpt)
Background/aim: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by bile duct destruction, cholestasis, and inflammation, often leading to fibrosis and cirrhosis. While ursodeoxycholic acid (UDCA) is the standard treatment, some patients exhibit suboptimal…